X

Trial Profile

A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domagrozumab (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

03 Apr 2022 This trial has been completed in Italy (Date of the global end of the trial : 11-Nov-2018), according to European Clinical Trials Database record.
03 Dec 2018 Planned End Date changed from 21 Nov 2018 to 1 Dec 2018.
03 Dec 2018 Planned primary completion date changed from 21 Nov 2018 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com